COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
18 hedge funds and large institutions have $681K invested in COSCIENS Biopharma Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
28% more capital invested
Capital invested by funds: $530K → $681K (+$151K)
6% more funds holding
Funds holding: 17 → 18 (+1)
0.02% less ownership
Funds ownership: 0.04% → 0.02% (-0.02%)
14% less call options, than puts
Call options by funds: $54K | Put options by funds: $63K
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$85.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.7K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$37.7K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$34K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$181K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$67K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$60K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$53.4K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$52K |
CSCI Hedge Fund Activity: Q3 2017 in Review
18 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2017, worth a combined $681K — up 28% from $530K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CSCI positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $85.6K. The largest seller was Renaissance Technologies, cutting an estimated $181K.
- 18 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2017, up from 17 in Q2 2017.
- Funds reported $681K of COSCIENS Biopharma Inc. Common Stock stock for Q3 2017, up 28% quarter-over-quarter.
- 7 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of +2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2017 was JP Morgan Chase, an estimated $85.6K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2017 was Renaissance Technologies, an estimated $181K sold.
Based on aggregated 13F filings for Q3 2017.